Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:BMY
CUSIP11012210
Phone212-546-4000
Debt
Debt-to-Equity Ratio0.46
Current Ratio1.40
Quick Ratio1.28
Price-To-Earnings
Trailing P/E Ratio20.27
Forward P/E Ratio16.66
P/E Growth1.5
Sales & Book Value
Annual Sales$20.78 billion
Price / Sales4.75
Cash Flow$3.5777 per share
Price / Cash16.86
Book Value$7.24 per share
Price / Book8.33
Profitability
EPS (Most Recent Fiscal Year)$3.01
Net Income$1.01 billion
Net Margins1.74%
Return on Equity42.58%
Return on Assets16.65%
Miscellaneous
Employees23,700
Outstanding Shares1,634,540,000
Market Cap$96.94 billion
Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions
What is Bristol-Myers Squibb's stock symbol?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?
Bristol-Myers Squibb announced a quarterly dividend on Thursday, June 14th. Shareholders of record on Friday, July 6th will be given a dividend of $0.40 per share on Wednesday, August 1st. This represents a $1.60 annualized dividend and a yield of 2.65%. The ex-dividend date is Thursday, July 5th. View Bristol-Myers Squibb's Dividend History.
How were Bristol-Myers Squibb's earnings last quarter?
Bristol-Myers Squibb Co (NYSE:BMY) issued its quarterly earnings results on Thursday, July, 26th. The biopharmaceutical company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.87 by $0.14. The biopharmaceutical company had revenue of $5.70 billion for the quarter, compared to analysts' expectations of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The firm's quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.74 earnings per share. View Bristol-Myers Squibb's Earnings History.
When is Bristol-Myers Squibb's next earnings date?
What guidance has Bristol-Myers Squibb issued on next quarter's earnings?
Bristol-Myers Squibb updated its FY18 earnings guidance on Thursday, July, 26th. The company provided EPS guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus estimate of $3.41.
What price target have analysts set for BMY?
19 brokers have issued 1-year price targets for Bristol-Myers Squibb's stock. Their predictions range from $51.00 to $78.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $62.9665 in the next year. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for Bristol-Myers Squibb.
What is the consensus analysts' recommendation for Bristol-Myers Squibb?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 12 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bristol-Myers Squibb.
Who are some of Bristol-Myers Squibb's key competitors?
Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Bristol-Myers Squibb's key executives?
Bristol-Myers Squibb's management team includes the folowing people:
- Dr. Giovanni Caforio, Chairman & CEO (Age 53)
- Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 58)
- Dr. Thomas J. Lynch Jr., Exec. VP of R&D & Chief Scientific Officer (Age 57)
- Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 57)
- Dr. Christopher S. Boerner, Pres & Head of U.S. Commercial (Age 47)
Has Bristol-Myers Squibb been receiving favorable news coverage?
News coverage about BMY stock has trended somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a coverage optimism score of 0.05 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.12 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Bristol-Myers Squibb.
Who are Bristol-Myers Squibb's major shareholders?
Bristol-Myers Squibb's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.85%), Jennison Associates LLC (1.07%), Bank of New York Mellon Corp (1.03%), FMR LLC (0.77%), Renaissance Technologies LLC (0.65%) and Legal & General Group Plc (0.49%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.
Which institutional investors are selling Bristol-Myers Squibb stock?
BMY stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Renaissance Technologies LLC, Bessemer Group Inc., Bank of New York Mellon Corp, Orbimed Advisors LLC, Putnam Investments LLC and Fred Alger Management Inc.. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Joseph C Caldarella, Sandra Leung and Thomas J Jr Lynch. View Insider Buying and Selling for Bristol-Myers Squibb.
Which institutional investors are buying Bristol-Myers Squibb stock?
BMY stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Point72 Asset Management L.P., Schroder Investment Management Group, MUFG Securities EMEA plc, Los Angeles Capital Management & Equity Research Inc., CIBC World Markets Inc. and Glenmede Trust Co. NA. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.
How do I buy shares of Bristol-Myers Squibb?
Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb's stock price today?
One share of BMY stock can currently be purchased for approximately $60.32.
How big of a company is Bristol-Myers Squibb?
Bristol-Myers Squibb has a market capitalization of $96.94 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.
How can I contact Bristol-Myers Squibb?
Bristol-Myers Squibb's mailing address is 430 E. 29th Street 14 Floor, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]
MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
